Basimglurant

Basimglurant
	File:Basimglurant.svg
Systematic (IUPAC) name
	2-chloro-4-{[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl]ethynyl}pyridine
Identifiers
CAS Number	802906-73-6
ATC code	none
PubChem	CID: 11438771
ChemSpider	9613635
Chemical data
Formula	C18H13ClFN3
Molecular mass	325.767 g/mol
	SMILES Clc3nccc(C#Cc2nc(n(c1ccc(F)cc1)c2C)C)c3 ;
	InChI InChI=1S/C18H13ClFN3/c1-12-17(8-3-14-9-10-21-18(19)11-14)22-13(2)23(12)16-6-4-15(20)5-7-16/h4-7,9-11H,1-2H3 ; Key:UPZWINBEAHDTLA-UHFFFAOYSA-N ;

Basimglurant (INN) (code names RG-7090, RO4917523) is a negative allosteric modulator of the mGlu₅ receptor which is under development by Roche for the treatment of treatment-resistant depression (as an adjunct) and fragile X syndrome.^[1]^[2] As of August 2014, it is in phase II clinical trials for both of these indications.^[1]^[2]

References

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.